Clinical Aspects of Janus Kinase (JAK) Inhibitors in the Cardiovascular System in Patients with Rheumatoid Arthritis
Kotyla, P.J.; Islam, M.A.; Engelmann, M. Clinical Aspects of Janus Kinase (JAK) Inhibitors in the Cardiovascular System in Patients with Rheumatoid Arthritis. Int. J. Mol. Sci. 2020, 21, 7390. https://doi.org/10.3390/ijms21197390
Kotyla PJ, Islam MA, Engelmann M. Clinical Aspects of Janus Kinase (JAK) Inhibitors in the Cardiovascular System in Patients with Rheumatoid Arthritis. International Journal of Molecular Sciences. 2020; 21(19):7390. https://doi.org/10.3390/ijms21197390
Chicago/Turabian StyleKotyla, Przemysław J., Md A. Islam, and Małgorzata Engelmann. 2020. "Clinical Aspects of Janus Kinase (JAK) Inhibitors in the Cardiovascular System in Patients with Rheumatoid Arthritis" International Journal of Molecular Sciences 21, no. 19: 7390. https://doi.org/10.3390/ijms21197390


